Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- One Big Beautiful Bill Act Implementation: What You Need to KnowThe One Big Beautiful Bill Act (OBBBA) became law on July 4, cutting more than $1 trillion in Medicaid funding and making substantial changes to the federal student loan program.
- ACC Chapters Increasing AED Access Across the USIncreasing access to AEDs has been a priority issue for several ACC State Chapters, guiding their advocacy efforts throughout the 2025 state legislative sessions. In the past year, more than 20 states have introduced related legislation, with ACC Chapters playing a major role in advocating for successful passage...
- Does Number of CVD Risk Factors Influence Plaque Vulnerability in ACS?The number of cardiovascular risk factors was strongly associated with greater plaque vulnerability, especially for culprit lesions, in patients with acute coronary syndromes (ACS), according to new research published in JACC.
- Better Cardiac Outcomes With Missense LMNA Variants Than Truncating VariantsTruncating LMNA variants are associated with worse arrhythmic outcomes regardless of variant location, whereas missense variants affecting the tail domain and located in exons 7-12 have better arrhythmic and heart failure (HF) outcomes...
- SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than SemaglutideTirzepatide leads to significantly greater loss of weight and weight circumference compared with semaglutide among adults with obesity but without diabetes, according to new results from the SURMOUNT-5 phase 3b trial, published in The New England Journal of Medicine.